低外科风险患者经导管与外科生物瓣主动脉瓣耐久性比较
TAVR 组与 SAVR 组全因死亡率相似(42.5% vs 37.7%,p=0.58),SAVR 组结构性瓣膜退化(SVD)率高于 TAVR 组(24.0% vs 4.8%,p<0.001),而生物瓣衰竭(BVF)率两组相似(6.7% vs 7.5%,p=0.89)。
要点
- 低外科风险患者 6 年全因死亡率 TAVR 与 SAVR 相似。
- SAVR 组结构性瓣膜退化率显著高于 TAVR 组。
- 两组生物瓣衰竭率低且相似。
核心结论
- 在 NOTION 试验 6 年随访中,SAVR 的结构性瓣膜退化显著高于 TAVR,而两组生物瓣衰竭率低且相似。
研究设计与样本
- NOTION 试验为随机对照试验,将低外科风险的重度主动脉瓣狭窄患者 1:1 随机分配至 TAVR(n=139)或 SAVR(n=135)。
主要发现
- 6 年全因死亡率 TAVR 组为 42.5%,SAVR 组为 37.7%(p=0.58)。
- 结构性瓣膜退化率 SAVR 组为 24.0%,TAVR 组为 4.8%(p<0.001)。
- 非结构性瓣膜退化率 SAVR 组为 57.8%,TAVR 组为 54.0%(p=0.52)。
- 感染性心内膜炎发生率 SAVR 组为 5.9%,TAVR 组为 5.8%(p=0.95)。
- 生物瓣衰竭率 SAVR 组为 6.7%,TAVR 组为 7.5%(p=0.89)。
关键数值与推荐
- 结构性瓣膜退化定义为平均跨瓣压差≥20 mm Hg、术后 3 个月起平均跨瓣压差增加≥10 mm Hg,或术后 3 个月起新发或加重的超过轻度的瓣内主动脉瓣反流。
- 非结构性瓣膜退化定义为术后 3 个月中重度患者-人工瓣膜不匹配或中重度瓣周漏。
- 生物瓣衰竭定义为瓣膜相关死亡、主动脉瓣再干预或严重血流动力学结构性瓣膜退化。
临床怎么用
- 在低外科风险重度主动脉瓣狭窄患者中,TAVR 与 SAVR 6 年生存及生物瓣衰竭率相似,但 SAVR 的结构性瓣膜退化率更高。
局限性
- 需更长期随机临床试验随访以确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and intermediate or high surgical risk. OBJECTIVES: The aim of this study was to compare the durability of transcatheter and surgical bioprosthetic aortic valves using standardized criteria. METHODS: In the NOTION (Nordic Aortic Valve Intervention) trial, all-comer patients with severe aortic stenosis and lower surgical risk for mortality were randomized 1:1 to TAVR (n = 139) or SAVR (n = 135). Moderate/severe structural valve deterioration (SVD) was defined as a mean gradient ≥20 mm Hg, an increase in mean gradient ≥10 mm Hg from 3 months post-procedure, or more than mild intraprosthetic aortic regurgitation (AR) either new or worsening from 3 months post-procedure. Nonstructural valve deterioration (NSVD) was defined as moderate/severe patient-prosthesis mismatch at 3 months or moderate/severe paravalvular leakage. Bioprosthetic valve failure (BVF) was defined as: valve-related death, aortic valve reintervention, or severe hemodynamic SVD. RESULTS: At 6 years, the rates of all-cause mortality were similar for TAVR (42.5%) and SAVR (37.7%) patients (p = 0.58). The rate of SVD was higher for SAVR than TAVR (24.0% vs. 4.8%; p < 0.001), whereas there were no differences in NSVD (57.8% vs. 54.0%; p = 0.52) or endocarditis (5.9% vs. 5.8%; p = 0.95). BVF rates were similar after SAVR and TAVR through 6 years (6.7% vs. 7.5%; p = 0.89). CONCLUSIONS: In the NOTION trial through 6 years, SVD was significantly greater for SAVR than TAVR, whereas BVF was low and similar for both groups. Longer-term follow-up of randomized clinical trials will be necessary to confirm these findings. (Nordic Aortic Valve Intervention Trial; NCT01057173).
引用
- Søndergaard L, Ihlemann N, Capodanno D, et al. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. J Am Coll Cardiol. 2019. PMID: 30732707. doi:10.1016/j.jacc.2018.10.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。